Decision to Acquire and Cancel 15th Series Convertible Bonds before Maturity (Response to Put Option Exercise)

Reason: Redemption due to bondholders' early redemption request (put option).
Acquisition amount: KRW 2,865,497,500 (including face value of KRW 2.5 billion and early redemption interest).
Remaining CB face value after acquisition: KRW 15 billion.
Future plan: All acquired bonds will be cancelled (deregistration).
Funding source: Own funds (over-the-counter purchase).
Conversion price: KRW 9,000 per share.
Impact: Cancellation reduces potential dilution; positive for financial health.

Filing: Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) Before Maturity After Issuance (15th Series)
Company: Vivozon Pharmaceutical (082800)
Submission: Vivozon Pharmaceutical Co., Ltd.
Receipt: 04-30-2026
Under KRX KOSDAQ Market Division